Edwards Lifesciences Corp VP Huimin Wang Sells 5,600 Shares (EW)
Edwards Lifesciences Corp (NYSE:EW) VP Huimin Wang unloaded 5,600 shares of the company’s stock in a transaction dated Thursday, June 5th. The stock was sold at an average price of $80.73, for a total transaction of $452,088.00. Following the transaction, the vice president now directly owns 31,549 shares in the company, valued at approximately $2,546,951. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Edwards Lifesciences Corp (NYSE:EW) traded up 0.51% during mid-day trading on Monday, hitting $80.81. The stock had a trading volume of 600,017 shares. Edwards Lifesciences Corp has a 1-year low of $60.62 and a 1-year high of $87.03. The stock’s 50-day moving average is $82.36 and its 200-day moving average is $72.08. The company has a market cap of $8.525 billion and a price-to-earnings ratio of 29.20.
Edwards Lifesciences Corp (NYSE:EW) last released its earnings data on Thursday, April 24th. The company reported $0.76 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.69 by $0.07. The company had revenue of $522.40 million for the quarter, compared to the consensus estimate of $523.10 million. During the same quarter last year, the company posted $0.72 earnings per share. Edwards Lifesciences Corp’s revenue was up 5.2% compared to the same quarter last year. Analysts expect that Edwards Lifesciences Corp will post $3.16 EPS for the current fiscal year.
A number of analysts have recently weighed in on EW shares. Analysts at CRT Capital raised their price target on shares of Edwards Lifesciences Corp from $87.00 to $90.00 in a research note on Thursday, May 22nd. They now have a “buy” rating on the stock. Separately, analysts at Canaccord Genuity raised their price target on shares of Edwards Lifesciences Corp from $86.00 to $96.00 in a research note on Wednesday, May 21st. They now have a “buy” rating on the stock. Finally, analysts at Leerink Swann raised their price target on shares of Edwards Lifesciences Corp from $90.00 to $93.00 in a research note on Friday, May 9th. Six analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $81.69.
Edwards Lifesciences Corporation (NYSE:EW) is focused on technologies that treat structural heart disease and critically ill patients.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.